{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:35:01Z","timestamp":1771511701689,"version":"3.50.1"},"reference-count":32,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Decorin (DCN), an extracellular matrix proteoglycan found in tumor surrounding tissues, is a natural inhibitor of tumor cell proliferation and invasion. We conducted a cross-sectional observation study to evaluate the association of the pathological stage with the levels of DCN in plasma or tumor surrounding tissue. Among 118 patients who underwent breast surgery, 35 were designated as carcinoma in situ (Stage 0), 39 were Stage I, and 44 were Stage II or III. The stromal expression of DCN was quantified using a semiquantitative digital image analysis after immunohistochemical staining. The concentration of DCN was evaluated with a specific ELISA. As we have previously shown, stromal DCN expression was attenuated in the patients with Stage I, whereas stromal and plasma DCN was elevated paradoxically in those with Stage II\/III. The elevated plasma DCN is an independent predictive factor of Stage II\/III by the multivariate logistic regression analysis. The plasma level of DCN was negatively correlated with stromal DCN expression only in patients with advanced disease (Stage II\/III). The plasma level of DCN could become a useful biomarker for patients in the advanced stages. Extensive studies and further assessments are warranted for evaluating the prognostic significance and tumor characteristics to understand the clinical significances of stromal and systemic DCN.<\/jats:p>","DOI":"10.3390\/jcm10235530","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T01:43:22Z","timestamp":1638323002000},"page":"5530","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Plasma Levels of Decorin Increased in Patients during the Progression of Breast Cancer"],"prefix":"10.3390","volume":"10","author":[{"given":"Tokuko","family":"Hosoya","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goshi","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-0445","authenticated-orcid":false,"given":"Tsuyoshi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-0114","authenticated-orcid":false,"given":"Iichiroh","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Hosoya","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Department of Specialized Surgeries, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Specialized Surgeries, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Uetake","sequence":"additional","affiliation":[{"name":"Department of Specialized Surgeries, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/ijc.23930","article-title":"Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs","volume":"123","author":"Goldoni","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/346281a0","article-title":"Negative regulation of transforming growth factor-beta by the proteoglycan decorin","volume":"346","author":"Yamaguchi","year":"1990","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2019.01.003","article-title":"Small Leucine Rich Proteoglycans (decorin, biglycan and lumican) in cancer","volume":"491","author":"Appunni","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3892\/or.2012.2040","article-title":"Significance of stromal decorin expression during the progression of breast cancer","volume":"28","author":"Oda","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16029","DOI":"10.1007\/s13277-016-5431-1","article-title":"Reduced decorin expression in the tumor stroma correlates with tumor proliferation and predicts poor prognosis in patients with I\u2013IIIA non-small cell lung cancer","volume":"37","author":"Hong","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.7150\/jca.17192","article-title":"Identifying DCN and HSPD1 as Potential Biomarkers in Colon Cancer Using 2D-LC-MS\/MS Combined with iTRAQ Technology","volume":"8","author":"Li","year":"2017","journal-title":"J. Cancer"},{"key":"ref_7","first-page":"7769","article-title":"Aberrant expression and localization of decorin in human oral dysplasia and squamous cell carcinoma","volume":"63","author":"Banerjee","year":"2003","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/ejh.12125","article-title":"Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration","volume":"91","author":"Kristensen","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"ref_9","first-page":"20965","article-title":"Deregulation of decorin and FHL1 are associated with esophageal squamous cell carcinoma progression and poor prognosis","volume":"8","author":"Ji","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_10","first-page":"1939","article-title":"Prognostic value of stromal decorin expression in patients with breast cancer: A meta-analysis","volume":"7","author":"Li","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mefford, D., and Mefford, J. (2012). Stromal Genes Add Prognostic Information to Proliferation and Histoclinical Markers: A Basis for the Next Generation of Breast Cancer Gene Signatures. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037646"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-71799-w","article-title":"Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma","volume":"10","author":"Patel","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.18632\/oncoscience.87","article-title":"Differential regulation of extracellular matrix protein expression in carcinoma-associated fibroblasts by TGF-\u03b21 regulates cancer cell spreading but not adhesion","volume":"1","author":"Bockstal","year":"2014","journal-title":"Oncoscience"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.biocel.2014.07.020","article-title":"Soluble biglycan as a biomarker of inflammatory renal diseases","volume":"54","author":"Hsieh","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1002\/ijc.25239","article-title":"Plasma decorin predicts the presence of esophageal squamous cell carcinoma","volume":"127","author":"Wu","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1010428317699112","DOI":"10.1177\/1010428317699112","article-title":"Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): Plausible diagnostic marker in urothelial carcinoma of bladder","volume":"39","author":"Appunni","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_17","first-page":"509","article-title":"Patients With Invasive Ductal Carcinoma Have Reduced Levels of Decorin Expression in Their Breast Tissue Compared to Patients With Fibroadenoma While Plasma Decorin Remains Unchanged","volume":"21","author":"Falakian","year":"2018","journal-title":"Arch. Iran. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kawaguchi, T., Yoshio, S., Sakamoto, Y., Hashida, R., Koya, S., Hirota, K., Nakano, D., Yamamura, S., Niizeki, T., and Matsuse, H. (2020). Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9040936"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"(2013). Kanda Y: Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl., 3, 452\u2013458.","DOI":"10.1038\/bmt.2012.244"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1042\/bj3220809","article-title":"Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-\u03b21 release","volume":"322","author":"Imai","year":"1997","journal-title":"Biochem. J."},{"key":"ref_22","first-page":"3054","article-title":"The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21","volume":"33","author":"Guiu","year":"2013","journal-title":"Oncogene"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/his.12188","article-title":"Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast","volume":"63","author":"Lambein","year":"2013","journal-title":"Histopathology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/jjco\/hyab040","article-title":"Histopathological atlas of desmoplastic reaction characterization in colorectal cancer","volume":"51","author":"Ueno","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Yanai, H., Yoshikawa, K., Ishida, M., Tsuta, K., Sekimoto, M., and Sugie, T. (2021). Presence of myxoid stromal change and fibrotic focus in pathological examination are prognostic factors of triple-negative breast cancer: Results from a retrospective single-center study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0245725"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"109354","DOI":"10.1016\/j.cellsig.2019.109354","article-title":"Tumor-specific inhibitory action of decorin on different hepatoma cell lines","volume":"62","author":"Reszegi","year":"2019","journal-title":"Cell. Signal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.18632\/oncotarget.23869","article-title":"Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment","volume":"9","author":"Zhang","year":"2018","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/gt.2009.142","article-title":"Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy","volume":"17","author":"Choi","year":"2009","journal-title":"Gene Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3389\/fonc.2020.00645","article-title":"Protective Role of Decorin in Primary Hepatocellular Carcinoma","volume":"10","author":"Reszegi","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.18632\/oncotarget.13972","article-title":"Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model","volume":"8","author":"Oh","year":"2016","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"ra75","DOI":"10.1126\/scisignal.2001868","article-title":"Signaling by the Matrix Proteoglycan Decorin Controls Inflammation and Cancer Through PDCD4 and MicroRNA-21","volume":"4","author":"Merline","year":"2011","journal-title":"Sci. Signal."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.matbio.2015.09.001","article-title":"Decorin is an autophagy-inducible proteoglycan and is required for proper in vivo autophagy","volume":"48","author":"Gubbiotti","year":"2015","journal-title":"Matrix Biol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/23\/5530\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:36:09Z","timestamp":1760168169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/23\/5530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":32,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["jcm10235530"],"URL":"https:\/\/doi.org\/10.3390\/jcm10235530","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,26]]}}}